Apar Pataer

3.6k total citations · 1 hit paper
32 papers, 1.4k citations indexed

About

Apar Pataer is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Apar Pataer has authored 32 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 14 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Apar Pataer's work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Diagnosis and Treatment (14 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Apar Pataer is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Diagnosis and Treatment (14 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Apar Pataer collaborates with scholars based in United States, China and Brazil. Apar Pataer's co-authors include Stephen G. Swisher, Neda Kalhor, William N. William, Ignacio I. Wistuba, Arlene M. Correa, Jack A. Roth, Matthew D. Hellmann, William D. Travis, Mark G. Kris and Valerie W. Rusch and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Apar Pataer

31 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

2014 416 citations Matthew D. Hellmann, Jamie E. Chaft et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Apar Pataer United States	18	876	715	293	217	186	32	1.4k
Elena Elimova Canada	21	710 0.8×	529 0.7×	364 1.2×	534 2.5×	185 1.0×	119	1.4k
Jeremy Cetnar United States	14	788 0.9×	905 1.3×	372 1.3×	189 0.9×	62 0.3×	42	1.4k
Jingyu Yu United States	15	439 0.5×	871 1.2×	286 1.0×	102 0.5×	177 1.0×	27	1.3k
Masato Shingyoji Japan	15	847 1.0×	514 0.7×	382 1.3×	99 0.5×	181 1.0×	67	1.3k
Loredana Vecchione Italy	18	444 0.5×	964 1.3×	542 1.8×	213 1.0×	63 0.3×	33	1.5k
Chiara Lazzari Italy	24	738 0.8×	883 1.2×	580 2.0×	71 0.3×	74 0.4×	67	1.5k
Sònia Pernas Spain	20	447 0.5×	1.1k 1.6×	413 1.4×	83 0.4×	312 1.7×	109	1.6k
K.A. Mason United States	11	440 0.5×	687 1.0×	288 1.0×	168 0.8×	123 0.7×	18	1.3k
Angela Listì Italy	19	538 0.6×	701 1.0×	420 1.4×	90 0.4×	40 0.2×	41	1.3k
B. Helfrich United States	13	581 0.7×	726 1.0×	698 2.4×	58 0.3×	193 1.0×	27	1.4k

Countries citing papers authored by Apar Pataer

Since Specialization

Citations

This map shows the geographic impact of Apar Pataer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Apar Pataer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Apar Pataer more than expected).

Fields of papers citing papers by Apar Pataer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Apar Pataer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Apar Pataer. The network helps show where Apar Pataer may publish in the future.

Co-authorship network of co-authors of Apar Pataer

This figure shows the co-authorship network connecting the top 25 collaborators of Apar Pataer. A scholar is included among the top collaborators of Apar Pataer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Apar Pataer. Apar Pataer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reuss, Joshua E., Cheuk Hong Leung, Nicolas Zhou, et al.. (2024). 1209MO Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159. Annals of Oncology. 35. S776–S777.

Feldman, Hope, Boris Sepesi, Cheuk Hong Leung, et al.. (2023). Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 167(4). 1444–1453.e4. 8 indexed citations

Pataer, Apar, Annikka Weissferdt, Arlene M. Correa, et al.. (2022). Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. JTO Clinical and Research Reports. 3(11). 100420–100420. 13 indexed citations

Pataer, Apar, Annikka Weissferdt, Ara A. Vaporciyan, et al.. (2021). Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. Journal of Thoracic Oncology. 16(8). 1289–1297. 32 indexed citations

Weissferdt, Annikka, Apar Pataer, Stephen G. Swisher, et al.. (2021). Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. Lung Cancer. 154. 76–83. 18 indexed citations

Weissferdt, Annikka, Apar Pataer, Ara A. Vaporciyan, et al.. (2020). Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clinical Lung Cancer. 21(4). 341–348. 75 indexed citations

Pataer, Apar, Bülent Özpolat, Neil R. Cashman, et al.. (2019). Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene. 39(4). 801–813. 21 indexed citations

Bircan, Ahmet, Nilgün Gürbüz, Apar Pataer, et al.. (2018). Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. Lung Cancer. 124. 31–39. 37 indexed citations

Pu, Xingxiang, Ran Zhang, Li Wang, et al.. (2018). Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. Journal of Translational Medicine. 16(1). 328–328. 11 indexed citations

10.

Weissferdt, Annikka, Boris Sepesi, Apar Pataer, et al.. (2018). Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC). Annals of Oncology. 29. viii680–viii680. 4 indexed citations

11.

Cascone, Tina, Kathryn A. Gold, Stephen G. Swisher, et al.. (2017). Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery. 105(2). 418–424. 20 indexed citations

12.

Gentile, Emanuela, Taro Oba, Jing Lin, et al.. (2017). Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics. Oncotarget. 8(29). 48222–48239. 6 indexed citations

13.

Hellmann, Matthew D., Jamie E. Chaft, William N. William, et al.. (2014). Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. The Lancet Oncology. 15(1). e42–e50. 416 indexed citations breakdown →

14.

William, William N., Apar Pataer, Neda Kalhor, et al.. (2013). Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after Neoadjuvant Chemotherapy. Journal of Thoracic Oncology. 8(2). 222–228. 104 indexed citations

15.

Guo, Chengcheng, Ruping Shao, Arlene M. Correa, et al.. (2013). Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC. Journal of Thoracic Oncology. 8(3). 301–308. 19 indexed citations

16.

Guo, Chengcheng, Haibo Lu, Wen Gao, et al.. (2013). Insulin-Like Growth Factor Binding Protein-2 Level Is Increased in Blood of Lung Cancer Patients and Associated with Poor Survival. PLoS ONE. 8(9). e74973–e74973. 39 indexed citations

17.

He, Yong, Zhen Zhou, Wayne L. Hofstetter, et al.. (2012). Aberrant Expression of Proteins Involved in Signal Transduction and DNA Repair Pathways in Lung Cancer and Their Association with Clinical Parameters. PLoS ONE. 7(2). e31087–e31087. 33 indexed citations

18.

Pataer, Apar, Neda Kalhor, Arlene M. Correa, et al.. (2012). Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy. Journal of Thoracic Oncology. 7(5). 825–832. 251 indexed citations

19.

He, Yong, Arlene M. Correa, Maria Gabriela Raso, et al.. (2011). The Role of PKR/eIF2α Signaling Pathway in Prognosis of Non-Small Cell Lung Cancer. PLoS ONE. 6(11). e24855–e24855. 34 indexed citations

20.

Takada, Yuhei, Haruyo Ichikawa, Apar Pataer, Stephen G. Swisher, & Bharat B. Aggarwal. (2006). Genetic deletion of PKR abrogates TNF-induced activation of IκBα kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation. Oncogene. 26(8). 1201–1212. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact